Nov. 18 (Bloomberg) -- Qiagen NV, the Dutch biotechnology company that has spent about $2 billion on acquisitions since 2004, is armed for yet more takeovers as it seeks additional gene-based tools to predict disease.
Nov. 18 (Bloomberg) -- Qiagen NV, the Dutch biotechnology company that has spent about $2 billion on acquisitions since 2004, is armed for yet more takeovers as it seeks additional gene-based tools to predict disease.
